EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines

Maximilian Klimpel iD, Monica Terrao, Nilakshi Ching, Vanessa Climenti, Thomas Noll iD, Vicky Pirzas, Holger Laux

Biotechnology and Bioengineering · 2023

DOI: 10.1002/bit.28413 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2023. Written by Maximilian Klimpel and 6 co-authors. Institution: Biopharmaceutical Product Development, CSL Behring Innovation GmbH, Marburg, Germany. Major MEDLINE topics: Lentivirus, Genetic Vectors. Cited 21 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CSL Behring.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The large‐scale production of clinical‐grade lentiviral vectors (LVs) for gene therapy applications is a remaining challenge. The use of adherent cell lines and methods like transient transfection are cost‐intensive and hamper process scalability as well as reproducibility. This study describes the use of two suspension‐adapted stable packaging cell lines, called GPRGs and GPRTGs, for the development of a scalable and serum‐free LV production process. Both stable packaging cell lines are based on an inducible Tet‐off system, thus requiring doxycycline removal for initiation of the virus production. Therefore, we compared different methods for doxycycline removal and inoculated three independent 5 L bioreactors using a scalable induction method by dilution, an acoustic cell washer and manual centrifugation. The bioreactors were inoculated with a stable producer cell line encoding for a LV carrying a clinically relevant gene. LV production was performed in perfusion mode using a cell retention device based on acoustic wave separation. Comparable cell‐specific productivities were obtained with all three methods and cumulative functional yields up to 6.36 × 10 11 transducing units per bioreactor were generated in a 234‐h long process, demonstrating the usability of stable Tet‐off cell lines for an easily scalable suspension process. Remarkably, cell viabilities >90% were maintained at high cell densities without compromising productivity throughout the whole process, allowing to further extend the process time. Given its low effects of toxicity during virus production, the presented cell lines are excellent candidates to develop a fully continuous LV production process to overcome the existing bottlenecks in LV manufacturing.

Subjects

MeSH terms (MEDLINE)

LentivirusGenetic VectorsDoxycyclineCell Culture TechniquesReproducibility of ResultsCell LinePerfusion

Author keywords

continuous bioprocessinglentiviral vectorlentiviral vector productionperfusionstable producer cell linesuspension cell line

Substances

Doxycycline

Authors and institutions

  • Biopharmaceutical Product Development, CSL Behring Innovation GmbH, Marburg, Germany.
  • Chair for Cell Culture Technology, University of Bielefeld, Bielefeld, Germany.

ORCID profiles: Maximilian Klimpel, Thomas Noll

Funding

  • CSL Behring

Cite

APA

Klimpel, M., Terrao, M., Ching, N., Climenti, V., Noll, T., Pirzas, V., & Laux, H. (2023). Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28413

Vancouver

Klimpel M, Terrao M, Ching N, Climenti V, Noll T, Pirzas V, et al. Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28413

BibTeX
@article{Klimpel2023,
  author = {Klimpel, Maximilian and Terrao, Monica and Ching, Nilakshi and Climenti, Vanessa and Noll, Thomas and Pirzas, Vicky and Laux, Holger},
  title = {Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  doi = {10.1002/bit.28413}
}
Start for free →